X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2754) 2754
Book Chapter (21) 21
Magazine Article (17) 17
Publication (8) 8
Newsletter (4) 4
Book / eBook (3) 3
Book Review (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2458) 2458
science & technology (1960) 1960
life sciences & biomedicine (1941) 1941
enoxaparin - therapeutic use (1849) 1849
female (1478) 1478
anticoagulants - therapeutic use (1426) 1426
male (1360) 1360
middle aged (993) 993
aged (909) 909
enoxaparin (851) 851
adult (697) 697
enoxaparin - administration & dosage (657) 657
cardiovascular system & cardiology (654) 654
treatment outcome (588) 588
enoxaparin - adverse effects (587) 587
anticoagulants (527) 527
anticoagulants - adverse effects (523) 523
anticoagulants - administration & dosage (503) 503
abridged index medicus (491) 491
fibrinolytic agents - therapeutic use (435) 435
hematology (433) 433
peripheral vascular disease (383) 383
risk factors (378) 378
heparin - therapeutic use (372) 372
cardiac & cardiovascular systems (359) 359
thromboembolism (341) 341
heparin (332) 332
aged, 80 and over (317) 317
pharmacology & pharmacy (315) 315
venous thromboembolism - prevention & control (315) 315
drug therapy (312) 312
venous thrombosis - prevention & control (312) 312
general & internal medicine (308) 308
heparin, low-molecular-weight - therapeutic use (305) 305
hemorrhage - chemically induced (298) 298
retrospective studies (280) 280
prospective studies (279) 279
surgery (266) 266
medicine, general & internal (246) 246
postoperative complications - prevention & control (241) 241
thrombosis (239) 239
thromboembolism - prevention & control (233) 233
enoxaparin - pharmacology (230) 230
venous thromboembolism (225) 225
medicine & public health (217) 217
time factors (213) 213
pregnancy (206) 206
myocardial infarction - drug therapy (205) 205
warfarin - therapeutic use (204) 204
drug therapy, combination (191) 191
venous thrombosis - drug therapy (191) 191
anticoagulants - pharmacology (176) 176
factor xa inhibitors (173) 173
dose-response relationship, drug (172) 172
low-molecular-weight heparin (170) 170
randomized controlled trials as topic (169) 169
health aspects (167) 167
care and treatment (165) 165
double-blind method (164) 164
adolescent (159) 159
animals (158) 158
follow-up studies (158) 158
drug administration schedule (157) 157
analysis (155) 155
low molecular weight heparin (151) 151
fibrinolytic agents - administration & dosage (148) 148
injections, subcutaneous (148) 148
heparin - adverse effects (147) 147
aspirin - therapeutic use (146) 146
pulmonary embolism - prevention & control (143) 143
acute disease (141) 141
prevention (141) 141
venous thrombosis - etiology (138) 138
enoxaparin - economics (136) 136
platelet aggregation inhibitors - therapeutic use (136) 136
rivaroxaban (135) 135
cardiology (133) 133
dosage and administration (132) 132
pulmonary embolism (132) 132
risk assessment (131) 131
thrombosis - prevention & control (129) 129
polysaccharides - therapeutic use (128) 128
young adult (128) 128
research (127) 127
heparin - administration & dosage (126) 126
venous thrombosis (125) 125
anticoagulation (124) 124
heart attacks (122) 122
venous thromboembolism - etiology (122) 122
angina, unstable - drug therapy (119) 119
fibrinolytic agents - adverse effects (118) 118
incidence (116) 116
glycosaminoglycans (112) 112
heparin, low-molecular-weight - administration & dosage (111) 111
clinical trials (107) 107
clinical trials as topic (107) 107
electrocardiography (107) 107
enoxaparin - pharmacokinetics (107) 107
acute coronary syndromes (106) 106
internal medicine (103) 103
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2683) 2683
Spanish (43) 43
Russian (38) 38
German (34) 34
French (29) 29
Portuguese (13) 13
Italian (9) 9
Polish (9) 9
Chinese (6) 6
Ukrainian (3) 3
Czech (2) 2
Finnish (2) 2
Norwegian (2) 2
Serbian (2) 2
Arabic (1) 1
Bulgarian (1) 1
Japanese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The American heart journal, ISSN 0002-8703, 11/2014, Volume 168, Issue 5, pp. 611 - 621
.... Anticoagulation uses 1 of 4 choices: bivalirudin, unfractionated heparin, enoxaparin, and fondaparinux... 
Cardiovascular | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
American journal of clinical dermatology, ISSN 1175-0561, 02/2016, Volume 17, Issue 1, pp. 11 - 22
Background Cutaneous lichen planus (CLP) is an inflammatory dermatosis. Its chronic relapsing course and frequently spontaneous regression hamper the... 
Life Sciences & Biomedicine | Dermatology | Science & Technology | Antifungal Agents - adverse effects | Glucocorticoids - therapeutic use | Griseofulvin - adverse effects | Photosensitizing Agents - therapeutic use | Humans | Calcitriol - adverse effects | Griseofulvin - therapeutic use | Male | Photosensitizing Agents - adverse effects | Dermatologic Agents - therapeutic use | Ficusin - therapeutic use | Administration, Cutaneous | Enoxaparin - therapeutic use | Calcitriol - therapeutic use | Lichen Planus - drug therapy | Dermatologic Agents - adverse effects | Photochemotherapy | Enoxaparin - adverse effects | Antifungal Agents - therapeutic use | Calcitriol - analogs & derivatives | Fibrinolytic Agents - adverse effects | Fibrinolytic Agents - therapeutic use | Ficusin - adverse effects | Non-Randomized Controlled Trials as Topic | Female | Acitretin - therapeutic use | Lichen Planus - radiotherapy | Acitretin - adverse effects | Glucocorticoids - adverse effects | Sulfasalazine - therapeutic use | Keratolytic Agents - therapeutic use | Lichen Planus - therapy | Keratolytic Agents - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | PUVA Therapy | Sulfasalazine - adverse effects
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
.... Our aim was to compare the use of rivaroxaban for extended thromboprophylaxis with short-term thromboprophylaxis with enoxaparin... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2010, Volume 363, Issue 26, pp. 2499 - 2510
In this clinical trial, rivaroxaban, an oral factor Xa inhibitor, was effective in the initial and continued treatment of symptomatic venous thromboembolism;... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Rivaroxaban | Vitamin K - antagonists & inhibitors | Injections, Subcutaneous | Female | Morpholines - adverse effects | Morpholines - therapeutic use | Acute Disease | Double-Blind Method | Venous Thrombosis - drug therapy | Administration, Oral | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Acenocoumarol - adverse effects | Intention to Treat Analysis | Pulmonary Embolism - drug therapy | Acenocoumarol - therapeutic use | Aged | Hemorrhage - chemically induced | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Health aspects | Risk factors | Anticoagulants | Bone surgery | Veins & arteries | Index Medicus | Abridged Index Medicus | Venous Thrombosis | Factor Xa | Hemorrhage | Life Sciences | Venous Thromboembolism | Thiophenes | Acenocoumarol | Vitamin K | Warfarin | Enoxaparin | Morpholines | Human health and pathology | Pulmonary Embolism | MEDICIN OCH HÄLSOVETENSKAP | Oral | MEDICAL AND HEALTH SCIENCES | Administration | chemically induced | drug therapy | Subcutaneous | antagonists & inhibitors | Injections | adverse effects | therapeutic use
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 388, Issue 10055, pp. 1995 - 2003
Journal Article